Neumora Therapeutics (NASDAQ:NMRA) Upgraded at Wall Street Zen

Neumora Therapeutics (NASDAQ:NMRA) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Several other research analysts have also recently weighed in on NMRA. Weiss Ratings upgraded Neumora Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, September 25th. HC Wainwright reiterated a “buy” rating on shares of Neumora Therapeutics in a research note on Tuesday, July 28th. Finally, Royal Bank Of Canada dropped their price target on shares of Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Neumora Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $6.57.

Neumora Therapeutics Stock Performance

NMRA opened at $0.50 on Friday. Neumora Therapeutics has a one year low of $0.32 and a one year high of $3.65. The company has a quick ratio of 4.50, a current ratio of 4.50 and a debt-to-equity ratio of 1.19. The business has a 50 day simple moving average of $0.69 and a two-hundred day simple moving average of $1.74.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.01. As a group, equities research analysts anticipate that Neumora Therapeutics will post -0.84 earnings per share for the current fiscal year.

Insider Activity

In other Neumora Therapeutics news, insider Daljit Singh Aurora sold 21,055 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $1.60, for a total transaction of $33,688.00. Following the transaction, the insider owned 48,750 shares in the company, valued at approximately $78,000. The trade was a 30.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last three months, insiders have sold 453,833 shares of company stock worth $701,219. 26.94% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. HBK Sorce Advisory LLC bought a new stake in shares of Neumora Therapeutics during the second quarter worth $26,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Neumora Therapeutics during the second quarter valued at approximately $44,000. AMG National Trust Bank purchased a new stake in shares of Neumora Therapeutics in the second quarter worth about $74,000. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Neumora Therapeutics in the 2nd quarter valued at $130,000. Finally, Bank of America Corp DE bought a new stake in shares of Neumora Therapeutics during the 2nd quarter valued at about $171,000. 47.65% of the stock is currently owned by institutional investors and hedge funds.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases. The company combines neuroscience, data science and machine-learning technologies to identify disease mechanisms, discover potential therapies and develop more targeted medicines for patients with neurological and neuropsychiatric disorders.

Neumora’s pipeline has included navacaprant, also known as NMRA-140, an investigational selective kappa opioid receptor antagonist being studied for major depressive disorder and related symptoms such as anhedonia, or the loss of interest and pleasure.